Patient Support Services Contact Us
Image: Coherus Investors

Overview

Investors

A FULLY INTEGRATED BIOPHARMACEUTICAL COMPANY WITH A ROBUST PIPELINE ACROSS MULTIPLE THERAPEUTIC AREAS INCLUDING ONCOLOGY, OPHTHALMOLOGY, AND IMMUNOLOGY.

Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.

In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. A BLA for toripalimab for the treatment of nasopharyngeal carcinoma is under review by the FDA with a target action date of December 23, 2022. Toripalimab is also being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. Coherus’ earlier-stage immuno-oncology pipeline includes CHS-006, a TIGIT-targeted antibody, being evaluated in combination with toripalimab, CHS-1000, a proprietary ILT4 antibody, and other immuno-therapies targeting novel pathways.

Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®, and CIMERLI™ (ranibizumab-eqrn), a biosimilar of Lucentis®, in the U.S., and expects to launch the FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh) in the U.S. in 2023.

Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.
 

News
11/08/22
– UDENYCA® net sales of $45.4 million in the third quarter 2022 – – CIMERLI ™ launched in the United States on October 3 rd – – Planning underway for 2023 commercial launches of toripalimab, YUSIMRY ™ and UDENYCA® OBI – – Conference call today at 5 p.m. ET – REDWOOD CITY, Calif. , Nov.
11/01/22
REDWOOD CITY, Calif. , Nov. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after market close on Tuesday, November 8th, 2022 . Starting at 5:00 p.m.
10/12/22
– Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations, regardless of PD-L1 expression – Supports combination development of toripalimab plus anti-TIGIT in
09/19/22
- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis ®  (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity - - Interchangeability designation and clinical equivalence to Lucentis provides confidence that existing Lucentis
Events & Presentations
There are currently no events scheduled.